Resmed trial disappoints, but thesis is intact

Scott Power


Preliminary results from the SERVE-HF trial using adaptive servo-ventilation (ASV) therapy in patients with chronic heart failure did not meet its survival endpoint and in fact, showed a safety signal in this patient population. While disappointing and likely to see shares trade lower overnight, we estimate the earnings impact from this patient population is nominal (less than 3%), it does not affect core obstructive sleep apnoea patients and the trial’s success was not backed into our estimates; thus, our thesis remains intact. We make modest changes to our estimates, with our DCF/PE/SOP-based target price decreasing to A$9.73. We maintain our Add rating.

1 stock mentioned

Scott Power
Scott Power
Senior Analyst

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...


No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.


Sign In or Join Free to comment